Clinical

Dataset Information

0

A Phase 1/2 Study of Azacitidine in Combination With Pembrolizumab and Epacadostat Advanced Solid Tumors including Lung and Colorectal Cancer


ABSTRACT: Primary objectives: • Part 1: To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD; or the maximum tested dose) of the combination in subjects with advanced or metastatic solid tumors. • Part 2: To evaluate the efficacy of the combination in subjects with previously treated Stage IIIB or Stage IV non–small cell lung cancer (NSCLC), Stage IV microsatellite stable (MSS) colorectal cancer (CRC), and other select solid tumors by assessing the objective response rate (ORR) per RECIST v1.1 at the MTD or maximum tested dose. Primary endpoints: • Part 1: Safety and tolerability will be assessed by monitoring the frequency, duration, and severity of adverse events (AEs); through physical examinations; by evaluating changes in vital signs and electrocardiograms (ECGs); and through clinical laboratory blood and urine sample evaluations. • Part 2: Objective response rate, defined as the percentage of subjects having a complete response (CR) or partial response (PR), will be determined by investigator assessment of radiographic disease as per RECIST v1.1.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Cancer Stage Iv,Non-small Cell Lung Cancer Stage Iv,Advanced Cancer,Non-small Cell Lung Cancer Stage Iiib,Subjects With Advanced Solid Tumors And Previously Treated Stage Iiib Or Stage Iv Non–small Cell Lung Cancer And Stage Iv Microsatellite Stable Colorectal Cancer

PROVIDER: 2536320 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2022-01-01 | E-MTAB-4030 | biostudies-arrayexpress
2011-11-21 | E-GEOD-32035 | biostudies-arrayexpress
2011-11-21 | GSE32035 | GEO
2016-12-15 | GSE91089 | GEO
| 2540836 | ecrin-mdr-crc
| 2538990 | ecrin-mdr-crc
| 2539846 | ecrin-mdr-crc
2015-11-11 | GSE66999 | GEO
| 2205534 | ecrin-mdr-crc
| 2541477 | ecrin-mdr-crc